Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-01

Study Completion Date

2023-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

OBJECTIVES

* To assess the levels of plasma carnitine in controls and hemodialysis patients.
* To give supplementary L-carnitine to study subjects for a duration of 5months.
* To compare the values of plasma carnitine before and after L carnitine supplementation.
* To assess the role of carnitine supplementation on biochemical and clinical parameters.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of L-carnitine Therapy on the Heart of Maintenance Hemodialysis Patients

NCT05673239

Renal Dialysis

COMPLETED PHASE4

Oral L-carnitine and Inflammatory and Nutritional Biomarkers in Maintenance Hemodialysis

NCT07249229

End-stage Renal Disease (ESRD) Hemodialysis

COMPLETED PHASE2

The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis

NCT00179179

End Stage Renal Disease

COMPLETED PHASE2

Dialysis Adequacy in Nutritional Status in Hemodialysis Patients

NCT06108856

Dialysis Adequacy

UNKNOWN

Early Administration of L-carnitine in Hemodialysis Patients

NCT00322322

Complication of Hemodialysis Hyperthyroidism Treated or Under Control

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

.ABSTRACT INTRODUCTION Dialysis therapy can cause a decrease in both free carnitine and plasma acyl carnitines after only six months of dialysis treatment. A positive correlation between AC/FC ratio and months on HD therapy has been reported. We investigate in this study the role of oral L-carnitine supplementation on anemia, blood pressure, cardiac dysfunction and muscle cramps in hemodialysis patients.

OBJECTIVES

* To assess the levels of plasma carnitine in controls and hemodialysis patients.
* To give supplementary L-carnitine to study subjects for a duration of 5months.
* To compare the values of plasma carnitine before and after L carnitine supplementation.
* To assess the role of carnitine supplementation on biochemical and clinical parameters.

STUDY DESIGN AND SETTING: It will be a case-control study, which will be conducted in the Department of Biochemistry, University of Karachi in collaboration with Nephrology ward of JPMC, Karachi in a period of one year after approval of synopsis.

METHOD: Total 120 subjects will be included in this study which will be divided into two groups. Group A will comprise of 60 subjects of Chronic renal failure who will be the control group. Group B will comprise of 60 subjects who will be on hemodialysis for more than 1 year. Blood samples will be taken after informed consent. Group B subjects will be given L-Carnitine supplementation for five months under strict monitoring. Physical, biochemical and clinical parameters of group B subjects will be compared before and after supplementation.

RESULTS: Data will be analyzed using SPSS version 21. Results will be shared after completion of research.

CONCLUSION: conclusion will be shared after completion of research.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemodialysis Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Subjects of group B oral intervention group were given oral L-carnitine supplementation in the form of L-Carnitine tablets 500 mg thrice daily under strict monitoring for 5 months. The vitals were monitored daily during the course of supplementation.

Subjects of group B intravenous group were given Intra venous L-Carnitine as a dose of 20mg/kg IV bolus infused over 2-3 minutes, administered into intra venous line after every hemodialysis session ( thrice a week) for 5 months.

Complete general physical examination was done on every dialysis session. Patients were strictly monitored for the development of any signs of distress during the course of supplementation the drug. The patients and their attendants were educated about monitoring the vitals at home daily and to inform nephrologist immediately in case of any signs of allergy or distress. The supplementation was given after obtaining ethical approval and informed consent and under direct supervision of a Nephrologist.

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intervention

L-Carnitine 500mg thrice daily

1g L-Carnitine IV three times a week

Group Type EXPERIMENTAL

L-Carnitine 500Mg thrice daily

Intervention Type DRUG

L-Carnitine 500mg oral thrice daily

1g L-Carnitine IV three times a week

Intervention Type DRUG

1g IV L-Carnitine three times a week

control

no intervention given

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L-Carnitine 500Mg thrice daily

L-Carnitine 500mg oral thrice daily

Intervention Type DRUG

1g L-Carnitine IV three times a week

1g IV L-Carnitine three times a week

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The study included people between the ages of 18 and 50 who had had dialysis for more than two years without taking additional antioxidants.

Exclusion Criteria

* • Individuals with any other chronic ailment, such as cancer or tuberculosis.

* Patients with acute renal failure who are receiving hemodialysis.
* All subjects who refused to take part in the investigation.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No